All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EBL-1463
Therapeutic Area: Infections and Infectious Diseases Product Name: EBL-1463
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: CARB-X
Deal Size: $5.8 million Upfront Cash: Undisclosed
Deal Type: Funding February 03, 2021
Details:
Mutabilis’ new intravenous drug, EBL-1463, is a novel class of non-beta-lactam inhibitor of penicillin binding proteins (PBPs) called dabocins. Mutabilis’ new drug aims to treat deadly ‘nightmare bacteria’ infections safely and effectively.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CoVepiT
Therapeutic Area: Infections and Infectious Diseases Product Name: CoVepiT
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Bpifrance
Deal Size: $6.3 million Upfront Cash: Undisclosed
Deal Type: Funding December 18, 2020
Details:
The French State's funding, totaling €5.8 million for the entire consortium and including €5.2 million for OSE Immunotherapeutics, will in particular support the CoVepiT 1 study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CoVepiT
Therapeutic Area: Infections and Infectious Diseases Product Name: CoVepiT
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
The human ex vivo clinical study, named CoVepiT 1, was conducted in 120 convalescent COVID-19 subjects versus unexposed subjects. Primary Objective Achieved in Human Ex Vivo Study. .
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VLA2001,CpG 1018
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: U.K. Government
Deal Size: $1,611.0 million Upfront Cash: Undisclosed
Deal Type: Partnership September 14, 2020
Details:
Valneva’s vaccine candidate, VLA2001, is based on a proven approach and will leverage the company’s existing manufacturing platform being used for its US FDA and EMA approved Japanese Encephalitis (JE) vaccine.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CoVepiT
Therapeutic Area: Infections and Infectious Diseases Product Name: CoVepiT
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2020
Details:
Data support potential as novel and differentiated COVID-19 vaccine designed against multiple SARS-CoV-2 targets with technology known to induce memory T lymphocytes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VLA2001
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: UK Government
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 20, 2020
Details:
Valneva has reached agreement in principle with the UK government to provide up to 100 million doses of its SARS-CoV-2 vaccine candidate, to be manufactured at its facilities in Livingston, Scotland.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Covepit
Therapeutic Area: Infections and Infectious Diseases Product Name: Covepit
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Nantes Metropole
Deal Size: $0.2 million Upfront Cash: Undisclosed
Deal Type: Funding July 16, 2020
Details:
OSE is working on the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2. This research program aims to develop a prophylactic vaccine focused on memory T cells and based on a multiepitope- peptide approach.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ANT3310,Meropenem
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2020
Details:
QIDP is granted to Antabio's MEM-ANT3310 for major hospital indications including nosocomial pneumonia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Peptide vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2020
Details:
Vaccine leverages expertise in peptide selection and optimization and proprietary Memopi® technology to explore a T lymphocyte immune response for COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
